首页 | 官方网站   微博 | 高级检索  
     


Reply to “Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma” by Mesbah Ardakani et al.
Authors:Amélie Boespflug  Elisa Funck‐Brentano  Zofia Hélias‐Rodzewicz  Delphine Maucort‐Boulch  Alain Beauchet  Pierre‐Paul Bringuier  Charles Dumontet  Jean‐François Emile  Philippe Saiag  Stéphane Dalle
Affiliation:1. Dermatology Unit, Hospices Civils de Lyon, Pierre‐Bénite, France;2. Cancer Research Center of Lyon, Claude Bernard Lyon–1 University, INSERM1052, CNRS 5286, Lyon,  3. France;4. Pathology Department, Hospices Civiles de Lyon, Pierre‐Bénite, France;5. Department of Dermatology, Ambroise Paré Hospital (AP‐HP), Boulogne‐Billancourt, France;6. Research Unit EA 4340 “Biomarkers in cancerology and in hemato‐oncology, University of Versailles‐Saint‐Quentin‐en‐Yvelines, Université Paris‐Saclay, Boulogne‐Billancourt, France;7. Laboratoire de Biométrie et Biologie Evolutive, Biostatistique‐Santé team, CNRS UMR 5558, Université Lyon 1, Villeurbanne, France;8. Department of Pathology, Ambroise Paré Hospital (AP‐HP), Boulogne‐Billancourt, France;9. Department of Public Health, Ambroise Paré Hospital (AP‐HP), Boulogne‐Billancourt, France;10. Medical Oncology Department, Institut de Cancerologie des Hospices Civils de Lyon, Pierre‐Bénite, France
Abstract:
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号